M. Chandesris, G. Damaj, D. Canioni
Jun 29, 2016
Citations
3
Influential Citations
55
Citations
Journal
The New England journal of medicine
Abstract
The use of midostaurin, a multikinase inhibitor, has been associated with a response in 60% of patients with systemic mastocytosis, including mast-cell leukemia; the median overall survival was 28 months. A second, smaller trial in France showed a 71% response rate.